amyloidosis
Information
- Disease name
- amyloidosis
- Disease ID
- DOID:9120
- Description
- "A disease of metabolsism that is characterized by extracellular tissue deposition of mis-folded amyloid fibrils built up by twisted protofilaments, deposited in the spaces between the cells of vital organs, causing disruption of organ tissue structure and function. These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition." [url:https\://en.wikipedia.org/wiki/Amyloidosis, url:https\://pubmed.ncbi.nlm.nih.gov/33100054/, url:https\://pubmed.ncbi.nlm.nih.gov/33787033/, url:https\://www.tandfonline.com/doi/pdf/10.1080/13506129.2020.1835263?needAccess=true]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02909036 | Active, not recruiting | Phase 1 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | September 2016 | September 2024 |
| NCT03584022 | Active, not recruiting | N/A | Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial | November 9, 2018 | March 2027 |
| NCT03431896 | Active, not recruiting | Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis | February 1, 2018 | December 31, 2026 | |
| NCT03201965 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis | October 5, 2017 | August 16, 2024 |
| NCT05199337 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | November 30, 2021 | December 2025 |
| NCT02924272 | Active, not recruiting | Phase 2 | Ixazomib Rollover Study | December 16, 2016 | February 22, 2027 |
| NCT05235269 | Active, not recruiting | Phase 2 | A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis | November 30, 2021 | December 30, 2022 |
| NCT04869631 | Active, not recruiting | Screening for Amyloidosis Before Aortic Valve Elective Replacement | February 1, 2021 | March 31, 2028 | |
| NCT01864018 | Active, not recruiting | Phase 1/Phase 2 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | August 20, 2013 | October 22, 2024 |
| NCT02260466 | Active, not recruiting | N/A | Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. | October 2014 | December 31, 2024 |
| NCT03123029 | Available | Expanded Access to Venetoclax | |||
| NCT01135849 | Completed | B-Receptor Signaling in Cardiomyopathy | November 2008 | October 2010 | |
| NCT01215747 | Completed | Phase 3 | Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis | November 2010 | March 2016 |
| NCT01273844 | Completed | N/A | Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) | March 1, 2011 | May 12, 2016 |
| NCT01323985 | Completed | Phase 1 | SAP Depleter Dose Escalation Study in Healthy Volunteers | January 6, 2011 | June 30, 2011 |
| NCT01383759 | Completed | N/A | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | June 24, 2011 | April 30, 2019 |
| NCT01406314 | Completed | Phase 1 | SAP Depleter Dose Assessment Study in Patients | October 13, 2011 | November 14, 2012 |
| NCT01432587 | Completed | The Effect of Diflunisal on Familial Transthyretin Amyloidosis | August 2011 | December 2014 | |
| NCT01527032 | Completed | Phase 2 | Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis | September 2002 | September 2005 |
| NCT01606280 | Completed | Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation | June 2011 | June 2013 | |
| NCT01677286 | Completed | Phase 2 | Safety and Effect of Doxycycline in Patients With Amyloidosis | July 2012 | December 15, 2015 |
| NCT01737398 | Completed | Phase 2/Phase 3 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | March 15, 2013 | November 7, 2017 |
| NCT01777243 | Completed | Phase 1 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | May 13, 2013 | December 22, 2015 |
| NCT01789242 | Completed | Phase 1 | A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis | February 2013 | July 2017 |
| NCT01998503 | Completed | Phase 3 | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | December 2007 | August 2013 |
| NCT02055534 | Completed | N/A | Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis | July 2007 | September 2013 |
| NCT02111538 | Completed | Body Composition in Systemic Amyloidosis | February 2014 | April 2019 | |
| NCT02158052 | Completed | N/A | Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease | February 2015 | June 22, 2021 |
| NCT02175004 | Completed | Phase 3 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) | June 26, 2014 | January 7, 2021 |
| NCT02245867 | Completed | Phase 1 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | December 2, 2014 | July 23, 2017 |
| NCT02338427 | Completed | N/A | Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis | May 2016 | November 2018 |
| NCT02485613 | Completed | Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis | January 2009 | March 2015 | |
| NCT02510261 | Completed | Phase 3 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) | July 16, 2015 | November 23, 2022 |
| NCT02545907 | Completed | Phase 1/Phase 2 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | September 14, 2017 | October 21, 2019 |
| NCT02555969 | Completed | Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | August 2015 | August 2020 | |
| NCT02574676 | Completed | Quality of Life (QOL) Registry for Patients With AL Amyloidosis | October 2015 | July 2018 | |
| NCT02587728 | Completed | Carpal Tunnel/Amyloidosis Blood Sample Study | February 24, 2016 | February 7, 2017 | |
| NCT02716103 | Completed | Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis | November 21, 2016 | September 4, 2020 | |
| NCT02791373 | Completed | Phase 2 | Vinorelbine and Gemcitabine in Myeloma | March 2014 | December 31, 2017 |
| NCT02792790 | Completed | Carpal Tunnel Syndrome and Amyloid Cardiomyopathy | March 2016 | December 2, 2021 | |
| NCT02816476 | Completed | Phase 2 | Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis | September 2016 | October 2020 |
| NCT05260203 | Completed | N/A | MargheRITA (Remote Intelligence for Therapeutic Adherence) | June 4, 2022 | January 16, 2023 |
| NCT00017680 | Completed | Phase 2 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | July 1999 | April 2004 |
| NCT00166413 | Completed | Phase 2 | Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis | April 2005 | |
| NCT00186407 | Completed | Phase 2 | Autologous Stem Cell Rescue for Primary Amyloidosis | April 1998 | February 2010 |
| NCT00298766 | Completed | Phase 1/Phase 2 | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis | June 2005 | September 2009 |
| NCT00607581 | Completed | Phase 2 | Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | February 2008 | January 2012 |
| NCT00621400 | Completed | Phase 1/Phase 2 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | January 2008 | December 2009 |
| NCT00890552 | Completed | N/A | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | April 2009 | October 2012 |
| NCT00919139 | Completed | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | November 2003 | November 2010 | |
| NCT00981708 | Completed | Phase 1/Phase 2 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | February 2008 | January 11, 2016 |
| NCT01083316 | Completed | Phase 2 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis | September 2009 | September 4, 2020 |
| NCT02953808 | Completed | Phase 1 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | November 2016 | December 2016 |
| NCT03019029 | Completed | Phase 1/Phase 2 | Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis | March 13, 2017 | March 22, 2022 |
| NCT03610035 | Completed | Phase 1 | A Study of NPT189 in Healthy Subjects | July 24, 2018 | February 17, 2019 |
| NCT03825224 | Completed | Evaluation of MyoStrain™ in Clinical Practice | April 15, 2019 | November 15, 2019 | |
| NCT03860935 | Completed | Phase 3 | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy | March 19, 2019 | May 11, 2023 |
| NCT03886155 | Completed | Cardiac Amyloidosis Screening at Trigger Finger Release | May 1, 2019 | December 2, 2021 | |
| NCT03923920 | Completed | Screening for Systemic Amyloidosis Via the Ligamentum Flavum | May 1, 2019 | December 2, 2021 | |
| NCT03959358 | Completed | Phase 2 | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | July 3, 2020 | October 7, 2022 |
| NCT03984721 | Completed | N/A | Amyloidosis Typing Using Mass Spectrometry-based Proteomics: a New Accurate Tool for Difficult Typing | July 25, 2019 | September 8, 2021 |
| NCT04068077 | Completed | Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis | March 8, 2019 | December 19, 2019 | |
| NCT04769479 | Completed | Phase 1 | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects | March 28, 2021 | September 3, 2021 |
| NCT04985734 | Not yet recruiting | N/A | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy | October 1, 2021 | July 1, 2025 |
| NCT05862961 | Not yet recruiting | Better Classification of Respiratory Amyloidosis | May 15, 2023 | May 15, 2026 | |
| NCT05259072 | Recruiting | Phase 3 | carDIo-ttranSSfOrm nucLEar Imaging Study | January 19, 2022 | December 30, 2026 |
| NCT05263817 | Recruiting | Early Phase 1 | A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis | October 8, 2021 | October 1, 2024 |
| NCT05283993 | Recruiting | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | July 1, 2021 | December 31, 2030 | |
| NCT05758493 | Recruiting | Phase 2 | Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis | January 10, 2023 | July 10, 2024 |
| NCT05577819 | Recruiting | N/A | Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF | October 2, 2020 | December 31, 2024 |
| NCT05556928 | Recruiting | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry | July 21, 2020 | December 31, 2024 | |
| NCT05793320 | Recruiting | N/A | Carpal Tunnel Release With Risk Factors for Amyloidosis | August 3, 2023 | December 3, 2024 |
| NCT05145816 | Recruiting | Phase 1/Phase 2 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | February 15, 2024 | September 1, 2026 |
| NCT05250973 | Recruiting | Phase 2 | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | March 1, 2022 | December 31, 2027 |
| NCT04636684 | Recruiting | N/A | Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis | December 1, 2020 | December 31, 2025 |
| NCT06414746 | Recruiting | Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia | December 29, 2023 | December 31, 2024 | |
| NCT05738005 | Recruiting | N/A | Dietary Reporting In The Amyloidoses | March 2, 2023 | November 21, 2025 |
| NCT04942067 | Recruiting | Phase 1/Phase 2 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | December 23, 2021 | December 1, 2024 |
| NCT05754099 | Recruiting | Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers. | March 1, 2022 | November 30, 2024 | |
| NCT05010980 | Recruiting | Early Detection of Cardiac Amyloidosis | August 1, 2021 | September 2023 | |
| NCT01347047 | Recruiting | HIBA-Institutional Registry of Amyloidosis | April 2011 | January 2030 | |
| NCT05950867 | Recruiting | N/A | Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause. | July 28, 2023 | June 1, 2026 |
| NCT06251778 | Recruiting | NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis | January 26, 2024 | January 26, 2026 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT04265040 | Recruiting | DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies | August 18, 2020 | December 2027 | |
| NCT03717844 | Recruiting | Registry for Adults With Plasma Cell Disorders (PCD's) | February 9, 2018 | February 2029 | |
| NCT03879278 | Terminated | Phase 1 | Multiple Ascending Dose Study in Healthy Subjects | March 6, 2019 | June 27, 2019 |
| NCT02590588 | Terminated | Phase 2 | Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis | January 2016 | March 27, 2017 |
| NCT03168906 | Terminated | Phase 2 | Renal AL Amyloid Involvement and NEOD001 | July 5, 2017 | February 6, 2019 |
| NCT03774784 | Terminated | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease | January 29, 2019 | May 18, 2020 | |
| NCT03044353 | Terminated | Phase 2 | Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 | July 10, 2017 | January 3, 2019 |
| NCT03417830 | Terminated | Phase 1 | Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging | April 6, 2018 | July 20, 2018 |
| NCT02603172 | Terminated | Phase 1 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | May 12, 2016 | May 10, 2017 |
| NCT04661800 | Unknown status | N/A | Study of Olfactory Disorders in Patients With Cardiac Amyloidosis | March 19, 2021 | December 1, 2022 |
| NCT03702829 | Unknown status | Phase 2 | 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients | February 28, 2019 | March 2022 |
| NCT04245098 | Unknown status | N/A | Carpal Tunnel Syndrome and Amyloidosis | January 8, 2020 | January 8, 2023 |
| NCT04456582 | Unknown status | N/A | Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elastography) in Patients With Transthyretin Amyloidosis | June 3, 2020 | May 29, 2021 |
| NCT02187263 | Unknown status | German Centre for Cardiovascular Research Cardiomyopathy Register | December 2014 | December 2017 | |
| NCT04893889 | Unknown status | N/A | Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. | September 9, 2020 | March 30, 2022 |
| NCT04913454 | Unknown status | N/A | CLearing Alzheimer's Disease Molecular Pathology Without Medications | August 1, 2021 | July 31, 2022 |
| NCT04983433 | Unknown status | Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and Pathology | August 5, 2021 | August 2022 | |
| NCT00004374 | Unknown status | Study of Systemic Amyloidosis Presentation and Prognosis | January 1979 | ||
| NCT05375279 | Unknown status | A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis | June 15, 2022 | March 31, 2023 | |
| NCT02627820 | Withdrawn | Phase 2 | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart | January 2016 | December 2018 |
| NCT00186095 | Withdrawn | N/A | Mixed Chimeric Transplantation for Primary Amyloidosis | December 2000 | September 2006 |
| NCT04984330 | Withdrawn | Early Phase 1 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | December 2021 | June 2024 |
| NCT03130348 | Withdrawn | Phase 2 | Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis | March 15, 2018 | April 2022 |
| NCT04943302 | Withdrawn | Phase 2 | Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis | September 2022 | January 2026 |
| NCT02462213 | Withdrawn | Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging | October 2013 | December 2017 | |
| NCT03825406 | Withdrawn | Prevalence of Wildtype Amyloid After TAVR | March 20, 2019 | March 20, 2019 | |
| NCT02589860 | Withdrawn | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant | October 30, 2015 | March 23, 2020 | |
| NCT03567499 | Withdrawn | Phase 1 | Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects | July 12, 2018 | May 3, 2019 |
- Disase is a (Disease Ontology)
- DOID:0014667
- Cross Reference ID (Disease Ontology)
- ICD10CM:E85
- Cross Reference ID (Disease Ontology)
- ICD9CM:277.3
- Cross Reference ID (Disease Ontology)
- MESH:D000686
- Cross Reference ID (Disease Ontology)
- NCI:C2868
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154769007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0002726
- Exact Synonym (Disease Ontology)
- amyloid disease
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0011034
- OrphaNumber from OrphaNet (Orphanet)
- 69
- ICD10 preferred id (Insert disease from ICD10)
- D0003943
- ICD10 class code (Insert disease from ICD10)
- E85
- MeSH unique ID (MeSH (Medical Subject Headings))
- D000686